Monitoring Phase II Comparative Clinical Trials with Two Endpoints and Penalty for Adverse Events
Adverse events in Phase II comparative clinical trials have received limited attention in the literature. Bersimis et al. (Stat Med 34:197–214, 2014) in proposed a class of comparative sequential designs with bivariate endpoints, where as a special case, the termination of the clinical trial due to the occurrence of a severe adverse event is treated. In this paper, using the Markov chain embedding technique, we extend this class of designs proposing two new designs, which treat cases where the development of an adverse event does not immediately stop the clinical trial, but penalizes appropriately the treatment that caused it. In both designs the penalty can be chosen either by assessing the severity of the adverse event or by optimizing the power. The numerical results show an excellent performance, achieving small expected sample sizes in conjunction with large values for power, satisfying in this way the ethical requirement for small sample sizes and fast decisions in clinical practice. The formulation of the procedure as a stochastic process is elegantly accomplished while it offers the necessary mathematical framework for further generalizing the designs covering more cases such as group sequential designs, etc.
KeywordsBivariate sequences of trials Clinical trials involving two binary endpoints Markov chain embeddable random variables Phase II clinical trials Decision rules Waiting time distribution Adverse events Penalization
Mathematics Subject Classification (2010)60J20 62P10
Unable to display preview. Download preview PDF.
S. Bersimis and A. Sachlas are supported by the Greek General Secretariat for Research and Technology research funding action “ARISTEIA II”. The authors would like to thank the Associate Editor and the two anonymous referees for their constructive comments that helped them to improve the manuscript.
- Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research. 4nd Ed., Blackell Science LtdGoogle Scholar